STOCK TITAN

Apnimed (NASDAQ: APMD) CEO’s options run to 2036 at $9.50 and $8.15

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Apnimed, Inc. (APMD) reported the initial beneficial ownership of its Chief Executive Officer, Kevin Robert Lind, in a Form 3. He holds stock options giving the right to purchase Class A Common Stock at exercise prices of $9.50 and $8.15, expiring in 2035 and 2036, respectively. These options cover 74,128 and 1,186,278 underlying shares and vest over time based on his continuous service, with 25% vesting after 12 months from the stated start dates and the remainder vesting in installments over the following 36 months.

Positive

  • None.

Negative

  • None.
Insider Lind Kevin Robert
Role Chief Executive Officer
Type Security Shares Price Value
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F2 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 1,260,406 shares (Direct)
Footnotes (2)
  1. F1. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
  2. F2. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Underlying Shares (Option 1) 74,128 shares Underlying Class A Common Stock for stock option at $9.5000 exercise price
Exercise Price (Option 1) $9.5000 per share Stock Option (Right to Buy) expiring March 6, 2035
Expiration Date (Option 1) 2035-03-06 Expiration of stock option with 74,128 underlying shares
Underlying Shares (Option 2) 1,186,278 shares Underlying Class A Common Stock for stock option at $8.1500 exercise price
Exercise Price (Option 2) $8.1500 per share Stock Option (Right to Buy) expiring June 23, 2036
Expiration Date (Option 2) 2036-06-23 Expiration of stock option with 1,186,278 underlying shares
Vesting Schedule (Option F1) 25% after 12 months, remainder over 36 months Quarterly vesting after March 6, 2025, subject to continuous service
Vesting Schedule (Option F2) 25% after 12 months, remainder over 36 months Monthly vesting after June 1, 2026, subject to continuous service
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying security title is Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion or exercise price is shown as 9.5000 and 8.1500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the shares subject to such option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"

FAQ

What does Apnimed (APMD) disclose in this Form 3 filing?

Apnimed (APMD) discloses its CEO Kevin Robert Lind’s initial beneficial ownership in company securities, specifically stock options to acquire Class A Common Stock, including their exercise prices, expiration dates, and time-based vesting schedules tied to his continuous service.

How many Apnimed (APMD) shares are covered by Kevin Lind’s reported stock options?

Kevin Lind’s reported options cover 74,128 and 1,186,278 underlying shares of Apnimed Class A Common Stock. These represent potential future share acquisitions if the options vest and are exercised according to the stated vesting and expiration terms.

What are the exercise prices of the stock options held by Apnimed (APMD) CEO Kevin Lind?

The reported stock options held by Kevin Lind have exercise prices of $9.50 and $8.15 per share. These prices are the amounts payable per share to acquire Apnimed Class A Common Stock upon exercise of the respective options.

When do Kevin Lind’s Apnimed (APMD) stock options expire?

The reported stock options for Apnimed CEO Kevin Lind expire on March 6, 2035 and June 23, 2036. After these expiration dates, any unexercised portion of the respective options would no longer be exercisable under the disclosed terms.

How do the vesting terms work for Kevin Lind’s Apnimed (APMD) stock options?

Each option vests 25% after 12 months of continuous service from its start date, with the remaining 75% vesting in substantially equal quarterly or monthly installments over the next 36 months, conditioned on his continuous service with Apnimed.

Does this Apnimed (APMD) Form 3 show any insider buying or selling?

No buying or selling is reported; the Form 3 lists existing stock option holdings for Kevin Lind. The transactions are classified as holdings entries, indicating positions rather than purchases or sales of Apnimed’s Class A Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Lind Kevin Robert

(Last)(First)(Middle)
APNIMED, INC.
39 JOHN F. KENNEDY STREET, 4TH FLOOR.

(Street)
CAMBRIDGE MASSACHUSETTS 02138

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
07/30/2026
3. Issuer Name and Ticker or Trading Symbol
Apnimed, Inc. [ APMD ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)03/06/2035Class A Common Stock74,128$9.5D
Stock Option (Right to Buy) (2)06/23/2036Class A Common Stock1,186,278$8.15D
Explanation of Responses:
1. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
2. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
/s/Kevin R. Lind07/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)